Points to Consider in the Development and Information Provision of Vaccines for Vaccination during Pregnancy: A Survey
Abstract
:1. Introduction
2. Methods
2.1. Classification for Deciding on Vaccination during Pregnancy
2.2. Vaccine Development Guidelines and SARS-CoV-2 Vaccine Response
3. Results
3.1. Classification for Deciding on Vaccination during Pregnancy
3.2. Vaccine Development Guidelines and SARS-CoV-2 Vaccine Response
3.2.1. Description of the Guidelines
3.2.2. Investigation of SARS-CoV-2 Vaccination during Pregnancy
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Sachdeva, P.; Patel, B.G.; Patel, B.K. Drug use in pregnancy; a point to consider. Indian J. Pharm. Sci. 2009, 71, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- WHO. Development Together the Vision and Strategy for Immunization 2021–2030. Available online: https://www.who.int/immunization/ia2030_Draft_Zero.pdf (accessed on 12 July 2020).
- Baxter, R.; Bartlett, J.; Fireman, B.; Lewis, E.; Klein, N.P. Effectiveness of Vaccination During Pregnancy to Prevent Infant Pertussis. Pediatrics 2017, 139, e20164091. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gray, K.J.; Bordt, E.A.; Atyeo, C.; Deriso, E.; Akinwunmi, B.; Young, N.; Baez, A.M.; Shook, L.L.; Cvrk, D.; James, K.; et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: A cohort study. Am. J. Obstet. Gynecol. 2021, 225, 303.e1–303.e17. [Google Scholar] [CrossRef] [PubMed]
- Faucette, A.N.; Pawlitz, M.D.; Pei, B.; Yao, F.; Chen, K. Immunization of pregnant women: Future of early infant protection. Hum. Vaccines Immunother. 2015, 11, 2549–2555. [Google Scholar] [CrossRef] [Green Version]
- Vojtek, I.; Dieussaert, I.; Doherty, T.M.; Franck, V.; Hanssens, L.; Miller, J.; Bekkat-Berkani, R.; Kandeil, W.; Prado-Cohrs, D.; Vyse, A. Maternal immunization: Where are we now and how to move forward? Ann. Med. 2018, 50, 193–208. [Google Scholar] [CrossRef] [Green Version]
- WHO Expert Committe on Biological Standardization. Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations; TRS 1004, Annex 9. WHO Tech Rep Ser No67; WHO: Geneva, Switzerland, 2017; Volume 1004, pp. 503–575. [Google Scholar]
- EMA. Draft Guideline on Clinical Evaluation of Vaccines. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-clinical-evaluation-vaccines-revision-1_en.pdf (accessed on 17 August 2022).
- EMA COMIRNATY (COVID-19 mRNA VACCINE) RISK MANAGEMENT PLAN Version Number: 5.0. Available online: https://www.ema.europa.eu/en/documents/rmp-summary/comirnaty-epar-risk-management-plan_en.pdf (accessed on 17 August 2022).
- FDA. Approval History, Letters, Reviews, and Related Documents—COMIRNATY. Available online: https://www.fda.gov/vaccines-blood-biologics/comirnaty (accessed on 17 August 2022).
- PMDA. Risk Management Plan of COMINRATY (only in Japanese). Available online: https://www.pmda.go.jp/RMP/www/672212/844b8dfe-491e-470f-ab0f-31f68e867f5e/672212_631341DA1025_016RMP.pdf (accessed on 17 August 2022).
- FDA. Approval History, Letters, Reviews, and Related Documents—SPIKEVAX. Available online: https://www.fda.gov/vaccines-blood-biologics/spikevax (accessed on 17 August 2022).
- PMDA. Risk Management Plan of SPIKEVAX (Only in Japanese). Available online: https://www.pmda.go.jp/RMP/www/400256/d250dd1b-2b3d-47f8-bcb3-08f2e7220b04/400256_631341EA1038_007RMP.pdf (accessed on 17 August 2022).
- EMA. Vaxzevria (Previously COVID-19 Vaccine AstraZeneca). EPAR Updat 16/04/2021. 2021;1:1-11. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca#authorisation-details-section (accessed on 17 August 2022).
- PMDA. Risk Management Plan of VAXZEVRIA (Only in Japanese). Available online: https://www.pmda.go.jp/RMP/www/670227/6bb360af-b4a5-4fcb-a6f4-bc9e7fe8466d/670227_631341FA1024_010RMP.pdf (accessed on 17 August 2022).
- EMA. European Union Risk Management Plan VAC31518 (Ad26.COV2.S). October 2022, Volume 4.2, pp. 1–153. Available online: https://www.ema.europa.eu/en/documents/rmp-summary/covid-19-vaccine-janssen-epar-risk-management-plan_en.pdf (accessed on 17 August 2022).
- FDA. Ixiaro package Insert and Patient Information. Available online: https://www.fda.gov/media/75777/download (accessed on 17 August 2022).
- Bouthry, E.; Picone, O.; Hamdi, G.; Grangeot-Keros, L.; Ayoubi, J.M.; Vauloup-Fellous, C. Rubella and pregnancy: Diagnosis, management and outcomes. Prenat. Diagn. 2014, 34, 1246–1253. [Google Scholar] [CrossRef] [PubMed]
- Enders, M.; Biber, M.; Exler, S. Masern, Mumps und Röteln in der Schwangerschaft. Mögliche Auswirkungen auf Mutter, Schwangerschaft und Fetus [Measles, mumps and rubella virus infection in pregnancy. Possible adverse effects on pregnant women, pregnancy outcome and the fetus]. Bundesgesundheitsblatt Gesundh. Gesundh. 2007, 50, 1393–1398. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. Yellow Fever Vaccine, Pregnancy, & Conception. Available online: https://www.cdc.gov/yellowfever/vaccine/vaccine-pregnancy.html (accessed on 4 September 2022).
- Sataples, J.E.; Gershman, M.; Fischer, M. Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunization Practices(ACIP). MMWR 2010, 59, 1–27. Available online: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5907a1.htm?s_cid=rr5907a1_w (accessed on 17 August 2022).
- Tsai, T.F.; Paul, R.; Letson, G.W. Congenital yellow fever virus infection after immunization in pregnancy. J. Infect Dis. 1993, 168, 1520–1523. [Google Scholar] [CrossRef] [PubMed]
- EMA. Signal Assessment Report on Embolic and Thrombotic Events (SMQ) with COVID-19 Vaccine (ChAdOx1-S [recombinant])—COVID-19 Vaccine AstraZeneca (Other Viral Vaccines). Available online: https://www.ema.europa.eu/en/documents/prac-recommendation/signal-assessment-report-Embolicthrombotic-events-smq-covid-19-vaccine-chadox1-s-recombinant-covid_en.pdf (accessed on 2 October 2022).
- EMA. Fluenz Tetra Product Information. Available online: https://www.ema.europa.eu/en/documents/product-information/fluenz-tetra-epar-product-information_en.pdf (accessed on 17 August 2022).
- EMA. Pandemic Influenza Vaccine H5N1 AstraZeneca Product Information. Available online: https://www.ema.europa.eu/en/documents/product-information/pandemic-influenza-vaccine-h5n1-astrazeneca-epar-product-information_en.pdf (accessed on 17 August 2022).
- EMA. Ixiaro Product Information. Available online: https://www.ema.europa.eu/en/documents/product-information/ixiaro-epar-product-information_en.pdf (accessed on 17 August 2022).
- FDA. Toxicology Review of IXIARO Vaccine. Available online: https://www.fda.gov/media/112535/download (accessed on 17 August 2022).
- Villar, J.; Ariff, S.; Gunier, R.B.; Thiruvengadam, R.; Rauch, S.; Kholin, A.; Roggero, P.; Prefumo, F.; do Vale, M.S.; Cardona-Perez, J.A.; et al. Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 Infection: The INTERCOVID multinational cohort study. JAMA Pediatr. 2021, 175, 817–826. [Google Scholar] [CrossRef]
- FDA. Toxicology Review of COVID-19 Vaccine (BNT162, PF-07302048). Available online: https://www.fda.gov/vaccines-blood-biologics/comirnaty (accessed on 4 September 2022).
- FDA. Clinical Reviews Memo, August 23.2021—COMIRNATY. Available online: https://www.fda.gov/vaccines-blood-biologics/comirnaty (accessed on 4 September 2022).
- FDA. Summary Basis for Regulatory Action—SPIKEVAX. Available online: https://www.fda.gov/media/155931/download (accessed on 4 September 2022).
- PMDA. Report on Special Approval for Emergency for Vaxzevria Intramuscular Injection. Available online: https://www.pmda.go.jp/files/000243208.pdf (accessed on 4 September 2022).
- Le, T.V.; Phan, L.T.; Ly, K.; Nguyen, L.T.; Nguyen, H.T.; Ho, N.; Trinh, T.X.; Tran Minh, N.N. Fatal avian influenza A(H5N1) infection in a 36-week pregnant woman survived by her newborn in Sóc Trăng Province, Vietnam, 2012. Influenza Other Respir. Viruses 2019, 13, 292–297. [Google Scholar] [CrossRef]
- Lyerly, A.D.; Little, M.O.; Faden, R. The second wave: Toward responsile inclusion of pregnant women in research. Int. J. Fem. Approaches Bioeth. 2008, 1, 5–22. [Google Scholar] [CrossRef] [PubMed]
Product Name | Trade Name (Japan) | Trade Name (USA) | Trade Name (Europe) |
---|---|---|---|
Pneumococcal 10-valent conjugate vaccine | — | — | Synflorix® (f) |
Pneumococcal 13-valent conjugate vaccine | Prevenar 13® (a) | Prevenar 13® (g) | Prevenar 13® (e) |
Pneumococcal 15-valent conjugate vaccine | — | Vaxneuvance® (g) | — |
Pneumococcal 20-valent conjugate vaccine | — | Prevenar 20® (g) | — |
Pnemococcal vaccine, polyvalent | PneumovaxNP® (a) | Pneumovax 23® (g) | — |
Hepatitis A vaccine | Aimmugen® (a) | Havrix® (g) | — |
Vaqta® (g) | |||
BCG vaccine | Freeze-dried glutamate BCG vaccine for percutaneous use (a) | BCG vaccine (e) | — |
TICE BCG® (e) | — | ||
Hepatitis B vaccine | Bimmugen® (a) | Engerix-B® (a) | HBVaxPro® (b) |
Heptavax-II® (a) | Recpmbivax HB® (g) | Fendrix® (b) | |
Heplisav B® (g) | Heplisav B® (b) | ||
Hepatitis B surface antigen (h) | — | ||
Hepatitis A and Hepatitis B vaccine | — | Twinrix® (g) | Ambirix® (a) |
Twinrix Adult® (d) | |||
Twinrix Paediatric® (d) | |||
Diphtheria, tetanus toxoids, and acellular pertussis adsorbed and inactivated poliovirus vaccine | Quattrovac® (h) | Kinrix® (h) | — |
Tetrabik® (h) | Quadracel® (h) | ||
SquareKids® (h) | |||
Product Name | Trade Name (Japan) | Trade Name (USA) | Trade Name (Europe) |
Diphtheria, tetanus toxoids, and acellular pertussis adsorbed, inactivated poliovirus and Haemophilus b conjugate (Tetanus toxoid conjugate) vaccine | — | Pentacel® (h) | — |
Diphtheria, tetanus toxoids, and acellular pertussis adsorbed, inactivated poliovirus, Haemophilus b conjugate (Meningococcal protein conjugate), and Hepatitis B (recombinant) vaccine | — | Vaxelis® (f) | Vaxelis® (f) |
Hexacima® (f) | |||
Infanrix Hexa® (f) | |||
Hexyon® (f) | |||
Diphtheria, tetanus toxoids, and acellular pertussis adsorbed vaccine | Tribik® (a) | Boostrix® (g) | — |
Infanrix® (h) | |||
Adacel Tdap® (g) | |||
Daptacel® (f) | |||
Diphteria and tetanus toxoids adsorbed (e) | |||
Diphtheria, tetanus toxoids, and acellular pertussis adsorbed vaccine, Hepatitis B (recombinant) and inactivated poliovirus combined vaccine | — | Pediarix® (h) | — |
Diphtheria and tetanus toxoids adsorbed vaccine | DTBik® (h) | Tdvax® (a) | — |
Diphtheria and tetanus toxoids “TAKEDA” (h) | Tetanus and diphtheria toxoids adsorbed injection (a) | ||
Human papillomavirus vaccine | Gardasil® (a) | Gardasil® (a) | —Gardasil® (c) |
Product Name | Trade Name (Japan) | Trade Name (USA) | Trade Name (Europe) |
Human papillomavirus vaccine | Silgard9® (a) | Gardasil9® (g) | Gardasil 9® (c) |
Cervarix® (c) | Cervarix® (c) | ||
Adenovirus vaccine | — | Live kit adenovirus Type 4 and Type 7 vaccine (e) | — |
Yellow fever vaccine | YF-Vax® (a) | YF-Vax® (a) | — |
Stamaril ®(a) | |||
Mumps vaccine | Freeze-dried live attenuated mumps vaccine “DAIICHI SANKYO” (e) | — | ― |
Haemophilus b conjugate vaccine | ActHIB® (h) | ActHIB® (f) | — |
PedvaxHIB® (f) | |||
Hiberix® (f) | |||
Haemophilus influenza Type B conjugate HIB (f) | |||
Influenza vaccine | Influenza HA vaccine “BIKEN” (a) | Fluad Quadrivalent® (f) | Supemtek® (b) |
Flubik HA® (a) | Fluarix Quadrivalent® (g) | Aflunov® (b) | |
Influenza HA vaccine “KMB” (a) | Flulaval Quadrivalent® (g) | Fluad Tetra® (e) | |
Influenza HA vaccine “SEIKEN” (a) | Flumist Quadrivalent® (a) | Fluenz Tetra® (f) | |
Influenza HA vaccine “DAIICHI SANKYO” (a) | Influenza A-H1N1 monovalent vaccine (a) | ||
Afluria Quadrivalent® (g) | |||
Flubik Quadrivalent Northern Hemisphere® (g) | |||
Flucelvax Quadrivalent® (g) | |||
Fluvirin® (h) | |||
Fluzone High-Dose Quadrivalent Northern Hemisphere® (f) | |||
Product Name | Trade Name (Japan) | Trade Name (USA) | Trade Name (Europe) |
Influenza vaccine (continue) | Fluzone Quadrivalent® (g) | ||
Influenzinum® (h) | |||
Medical provider single use EZ flu shot® (h) | |||
Pandemic influenza vaccine H5N1 “ASTRAZENECA” (b) | |||
Foclivia® (b) | |||
Adjupanrix® | |||
Pandemic influenza vaccine H5N1 “BAXTER AG” (a) | |||
Rabies vaccine | Rabipur® (a) | Rabavert® (a) | — |
Inactivated tissue culture rabies vaccine (a) | Imovax Rabies® (a) | ||
Ebola Zaire vaccine | — | Ervebo® (a) | Ervebo® (a) |
Mvabea® (a) | |||
Zabdeno® (a) | |||
Cholera vaccine | — | Vaxchora® (a) | Vaxchora® (b) |
Dukoral® (g) | |||
Typhoid vaccine | — | Typhim Vi® (a) | — |
Vivotif ®(a) | |||
COVID-19 vaccine | Comirnaty® (a) | COVID-19 vaccine “PFIZER-BIONTECH” (g) | Comirnaty® (b) |
COVID-19 vaccine “MODERNA” (a) | COVID-19 vaccine “MODERNA” (g) | COVID-19 vaccine “JANSSEN” (b) | |
COVID-19 vaccine “JANSSEN” (g) | Spikevax® (previously COVID-19 vaccine “MODERNA”) (b) | ||
Antigen component (h) | Vaxzevria® (b) | ||
Product Name | Trade Name (Japan) | Trade Name (USA) | Trade Name (Europe) |
Meningococcal conjugate vaccine | Menactra® (a) | Menactra® (g) | Nimenrix® (a) |
Menveo® (g) | Menveo® (a) | ||
Bexsero® (g) | Bexero® (a) | ||
MenQuadfi® (g) | MenQuadifi® (a) | ||
Trumenba® (g) | Trumenba® (a) | ||
Zoster vaccine | Shingrix® (a) | Shingrix® (g) | Shingrix® (d) |
Zostavax® (e) | Zostavax® (e) | ||
Tuberculin skin test | Freeze-dried tuberculin purified protein derivative (h) | — | — |
Tick-borne encephalitis vaccine | — | Ticovac® (g) | — |
Anthrax vaccine | — | Biothrax® (a) | — |
Dengue vaccine | — | Dengvaxia® (g) | Dengvaxia® (e) |
Smallpox vaccine | — | ACAM2000® (a) | Imvanex® (d) |
Japanese encephalitis virus vaccine | Encevac® (a) | Ixiaro® (a) | Ixiaro® (d) |
Jebik V® (a) | |||
Measles, mumps, rubella, and varicella virus live vaccine | — | Proquad® (e) | — |
Tetanus and diphtheria toxoids adsorbed vaccine | Adsorbed tetanus toxoid “SEIKEN” (a) | Tenivac® (g) | — |
Adsorbed tetanus toxoid “KAKEDA” (a) | |||
Tetanus toxoid “BIKEN F” (a) | |||
Rubella vaccine | Dried live attenuated rubella vaccine “TAKEDA” (e) | — | — |
Measles, mumps, and rubella virus vaccine | — | M-M-R II® (e) | — |
Poliovirus vaccine | Imovax Polio® (h) | IPOL® (a) | |
Product Name | Trade Name (Japan) | Trade Name (USA) | Trade Name (Europe) |
Measles and rubella vaccine | Mearubik (e) | — | MM-R VaxPro® (e) |
Freeze-dried live attenuated measles and rubella combined vaccine “DAIICHI SANKYO” (e) | |||
Freeze-dried live attenuated measles and rubella combined vaccine “TAKEDA” (e) | |||
Freeze-dried live attenuated measles and rubella combined vaccine “HOKKEN” (e) | |||
Measles vaccine | Dried live attenuated measles vaccine (e) | ― | |
Measles, mumps, rubella, and varicella virus vaccine | — | ― | ProQuad® (e) |
Rotavirus vaccine | Rotarix® (h) | Rotarix® (h) | Rotarix® (f) |
RotaTeq® (h) | RotaTeq® (f) | RotaTeq® (f) |
Comirnaty® | Spikevax® | Vaxzevria® | Janssen COVID-19 Vaccine |
---|---|---|---|
Clinical trial for pregnant women (USA) | Real-world effectiveness study (USA) | Clinical trial for pregnant women (Europe) | |
Observational studies using existing data sources (USA, Europe) | Observational studies using existing data sources (Europe) | Observational studies using existing data sources (Europe) | Observational studies using existing data sources (Europe) |
Registry investigation (USA, Europe) | Registry investigation (USA, Europe) | Registry Investigation (Europe) | Registry investigation (Europe) |
Cohort study (USA) | Observational study (USA) | ||
Use-results survey (Japan) | Use-results survey (Japan) | Use-results survey (Japan) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nomura, Y.; Oohashi, Y.; Shikano, M. Points to Consider in the Development and Information Provision of Vaccines for Vaccination during Pregnancy: A Survey. Vaccines 2022, 10, 1684. https://doi.org/10.3390/vaccines10101684
Nomura Y, Oohashi Y, Shikano M. Points to Consider in the Development and Information Provision of Vaccines for Vaccination during Pregnancy: A Survey. Vaccines. 2022; 10(10):1684. https://doi.org/10.3390/vaccines10101684
Chicago/Turabian StyleNomura, Yumiko, Yuusuke Oohashi, and Mayumi Shikano. 2022. "Points to Consider in the Development and Information Provision of Vaccines for Vaccination during Pregnancy: A Survey" Vaccines 10, no. 10: 1684. https://doi.org/10.3390/vaccines10101684